The Synthesis and Evaluation of Cyclic Ureas As HIV Protease Inhibitors: Modifications of the P1/P1' Residues

Overview

Journal Bioorg Med Chem Lett

Specialty Biochemistry

Date 1999 Jan 1

PMID 9871548

Citations 3

Authors

M Patel

L T Bacheler

M M Rayner

B C Cordova

R M Klabe

S P Seitz

Affiliations

Soon will be listed here.

Abstract

Two series of cyclic ureas modified at the P1/P1' residue were prepared and evaluated for HIV protease inhibition and whole cell antiviral activity. Compounds 8b, 10 (3- and 4-pyridylmethyl analogs) and 6b (4-methoxy analog) showed significant improvement in antiviral activity relative to lead compounds DMP323 and DMP 450.

Citing Articles

prediction of mozenavir as a potential drug for SARS-CoV-2 infection via binding multiple drug targets.

Mamidala E, Davella R, Praveen Kumar M, Swamy S, Abhiav M, Kaimkhani Z Saudi J Biol Sci. 2021; 29(2):840-847.

PMID: 34690521 PMC: 8522677. DOI: 10.1016/j.sjbs.2021.10.023.

Identification of novel HIV 1--protease inhibitors: application of ligand and structure based pharmacophore mapping and virtual screening.

Yadav D, Paliwal S, Yadav R, Pal M, Pandey A PLoS One. 2012; 7(11):e48942.

PMID: 23145032 PMC: 3493599. DOI: 10.1371/journal.pone.0048942.

Multiple receptor conformation docking and dock pose clustering as tool for CoMFA and CoMSIA analysis - a case study on HIV-1 protease inhibitors.

Sivan S, Manga V J Mol Model. 2011; 18(2):569-82.

PMID: 21547550 DOI: 10.1007/s00894-011-1048-x.